6 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $61M | -$11M | 65.8% | -13.3% | -35.9% | -12.1% | — | $25M | $24M |
| 2024 | $55M | -$15M | 62.1% | -24.8% | -73.1% | -18.3% | -$24M | $25M | $20M |
| 2023 | $60M | -$4M | 61.6% | -3.5% | -18.9% | -5.0% | $240000 | $15M | $27M |
| 2022 | $71M | -$30M | 56.7% | -38.8% | -174.5% | -28.2% | -$34M | $28M | $32M |
| 2021 | $63M | -$44M | 49.2% | -55.2% | -104.6% | -45.2% | — | — | $49M |
| 2020 | $45M | $5M | 67.2% | 17.6% | 51.3% | 10.2% | — | — | $8M |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $18M | -$312000 | 65.6% | 2.6% | -1.0% | -0.3% | — | $25M | $26M |
| Mar '26 | $16M | -$2M | 60.9% | -9.4% | -7.2% | -2.4% | — | $25M | $27M |
| Dec '25 | $16M | -$1M | 0.0% | -2.8% | -3.9% | -1.3% | — | $25M | $24M |
| Sep '25 | $17M | -$2M | 0.0% | -9.0% | -8.9% | -2.7% | — | $25M | $25M |
| Jun '25 | $15M | -$4M | 67.1% | -19.2% | -19.7% | -4.7% | — | $25M | $20M |
| Mar '25 | $13M | -$4M | 63.5% | -25.3% | -18.9% | -4.8% | — | $25M | $21M |
| Dec '24 | $13M | $2M | 82.3% | 17.7% | 7.6% | 1.9% | — | $25M | $20M |
| Sep '24 | $15M | -$2M | 63.9% | -19.8% | -21.9% | -3.7% | — | $20M | $22M |
| Jun '24 | $15M | -$3M | 56.0% | -19.7% | -29.8% | -5.2% | — | $20M | $24M |
| Mar '24 | $13M | -$10M | 47.7% | -77.4% | -80.6% | -15.7% | — | $15M | $24M |
| Dec '23 | $15M | -$2M | 85.3% | -13.8% | -10.5% | -2.8% | -$17M | $15M | $27M |
| Sep '23 | $15M | $17M | 57.9% | 112.9% | 96.6% | 25.5% | $19M | $0 | $25M |
| Jun '23 | $17M | -$8M | 54.2% | -45.1% | -167260.0% | -12.0% | $4M | $10M | $8M |
| Mar '23 | $12M | -$10M | 47.0% | -78.6% | -135.3% | -10.6% | -$6M | $23M | $17M |
| Dec '22 | $16M | -$11M | 51.5% | -62.8% | -62.7% | -10.1% | -$4M | $28M | $32M |
| Sep '22 | $16M | -$10M | 55.0% | -59.2% | -38.5% | -9.3% | -$7M | $20M | $35M |
| Jun '22 | $18M | -$8M | 58.1% | -39.2% | -21.6% | -6.6% | -$3M | $15M | $38M |
| Mar '22 | $21M | -$1M | 60.6% | -4.3% | -3.3% | -1.1% | -$19M | $15M | $41M |
| Dec '21 | $18M | -$22M | 45.6% | -51.7% | -51.7% | -22.4% | — | — | $49M |
| Sep '21 | $20M | -$11M | 43.1% | -64.5% | 90.9% | -12.0% | — | — | — |
How the market has priced DERM against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Journey Medical Corp's revenue has grown 6.6% per year. These are computed facts, not advice.
As of FY2025, Journey Medical Corp reported $25M of total debt against $24M of cash; operating income covered interest expense -2.2×.
In FY2025, gross margin was 65.8%, operating margin -13.3%, and net margin -18.7%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), split-adjusted; price return — dividends not reinvested · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.